Capillary Biomedical is developing a 7-day infusion set to solve the weak link in insulin pump therapy. This product, currently in early human clinical trials, will dramatically reduce the burden on people with diabetes and the overall healthcare system.


Over 1 million insulin pump users worldwide, each changing their infusion sets every 3 days


Insulin pump users insert over 120 million infusion sets each year


Over $2.7 billion spent on insulin pump therapy

More than 1,000,000 people with diabetes on insulin pump therapy are required to change their insulin infusion catheter every two to three days. Our technology could reduce the number of infusion set changes by up to 70 million per year.

“The type 1 diabetes community will greatly benefit from next-generation devices that help maintain glucose control safely and conveniently. We believe advancing infusion set technology will improve those devices and the overall quality of life for people living with T1D.”


Aaron Kowalski, JDRF Chief Mission Officer and Vice President of Research.

Find out more

Capillary Biomedical’s SteadiSet infusion set

with SteadiFlow technology

“Our goal is to develop an infusion set that will allow people who use insulin pumps to receive more reliable insulin delivery. ”

Discover More

Research Collaboration and Funding

Capillary Biomedical thanks our leading research collaboration and funding partners.

The Sidney Kimmel Medical College of Thomas Jefferson University

Capillary Biomedical licenses intellectual property from Thomas Jefferson University and collaborates on CSII catheter development.

Pioneering Research Funding Collaborations for Artificial Pancreas Technology

Capillary Biomedical is supported with funding from JDRF, the leading global organization funding type 1 diabetes research.

Supporting Innovative Research in Diabetes Science and Technology

Capillary Biomedical has been awarded an SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases.

Improving Lives by Supporting Health and Place-Based Initiatives in the U.S. and Globally

Capillary Biomedical has received a $1.5M program related investment in the form of a loan from the Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology

We’d love to hear from you. Click below to leave your information.

Contact Us Now